Active Ingredient History
Salinosporamide A (Marizomib) is a potent proteasome inhibitor being studied as a potential anticancer agent. It entered phase I human clinical trials for the treatment of multiple myeloma, only three years after its discovery in 2003. This marine natural product is produced by the obligate marine bacteria Salinispora tropica and Salinispora arenicola, which are found in ocean sediment. Salinosporamide A belongs to a family of compounds, known collectively as salinosporamides, which possess a densely functionalized γ-lactam-β-lactone bicyclic core. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Brain Neoplasms (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Diffuse Intrinsic Pontine Glioma (Phase 1)
Ependymoma (Phase 2)
Glioblastoma (Phase 3)
Glioma (Phase 2)
Gliosarcoma (Phase 1)
Lymphoma (Phase 1)
Melanoma (Phase 1)
Multiple Myeloma (Phase 2)
Neoplasms (Phase 1)
Pancreatic Neoplasms (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue